Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Zhejiang University is the lead sponsor of 110 current clinical trials in our China register. 71 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The drugs named most often in its trials are Gemcitabine, Sintilimab and Capecitabine. The most-studied condition is Colorectal Cancer.

ClinicalTrials.gov trials by status

Recruiting7165%
Not yet open3128%
Active, closed76%
By invitation11%

Trials by phase

Phase EARLY_PHASE13229%
Not applicable2725%
Phase 21715%
Observational1312%
Phase 1109%
Phase 1/276%
Phase 333%
Phase 411%

Clinical trials sponsored by Zhejiang University

110 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients NCT06770452 · Metastatic Pancreatic Carcinoma Drugs: Gemcitabine, HRS-4642, Nab-paclitaxel	Phase 2	Recruiting	2025-03	China
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer NCT05923255 · Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer	Not applicable	Recruiting	2023-05	China
Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1 NCT05593458 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Carcinoma Drug: Tegafur Gimeracil Oteracil	Phase 3	Recruiting	2023-03	China
Hepatic Artery Transfusion of NKG2D CAR-NK Cells Followed by Intravenous Infusion of NKG2D CAR-T Cells to Treat Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments: a Phase I Exploratory Clinical Trial NCT07021534 · ClinicalTrials.gov ↗ · Patients With Advanced Solid Tumors With Liver Metastases Who Have Failed Standard Treatments	Phase 1	Recruiting	2025-06	China
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors NCT06937567 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Colorectal Carcinoma, Gastric Cancer, Metastatic	Phase EARLY_PHASE1	Recruiting	2024-12	China
Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP NCT07607990 · ClinicalTrials.gov ↗ · Prostate Cancer (Post Prostatectomy), Perioperative Anesthetic, Catheter-related Bladder Discomfort (CRBD)	Not applicable	Recruiting	2026-01	China
COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial NCT06796764 · ClinicalTrials.gov ↗ · Hypoxia, Esophageal Cancer, Gastric Cancer	Not applicable	Recruiting	2025-04	China
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma NCT06633341 · ClinicalTrials.gov ↗ · T-lymphoblastic Lymphoma	Phase EARLY_PHASE1	Recruiting	2024-10	China
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase EARLY_PHASE1	Recruiting	2025-09	China
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases NCT06279923 · ClinicalTrials.gov ↗ · Autoimmune Diseases	Phase EARLY_PHASE1	Recruiting	2024-04	China
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma NCT06956716 · ClinicalTrials.gov ↗ · Advanced Intrahepatic Cholangiocarcinoma Drugs: Cisplatin, Gemcitabine, Sintilimab	Phase 1/2	Recruiting	2025-04	China
A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension NCT07080697 · ClinicalTrials.gov ↗ · Acute Necrotizing Pancreatitis, Portal Hypertension	Not applicable	Recruiting	2025-07	China
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies NCT04532281 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue	Phase EARLY_PHASE1	Recruiting	2020-11	China
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas NCT05433935 · ClinicalTrials.gov ↗ · Intraductal Papillary Mucinous Neoplasm	Observational	Recruiting	2022-07	China
Enucleation of Pancreatic Tumor by Blocking Abdominal Trunk and Superior Mesenteric Artery NCT06164769 · ClinicalTrials.gov ↗ · Tumor of Pancreas, Surgical Blood Loss	Not applicable	Recruiting	2023-03	China
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases NCT07581912 · ClinicalTrials.gov ↗ · Colorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors, Fulzerasib Drug: Fulzerasib	Phase 2	Recruiting	2026-04	China
A Study to Evaluate Safety and Feasibility of Robotic Liver Resection NCT06353672 · ClinicalTrials.gov ↗ · Liver Diseases, Surgery	Not applicable	Recruiting	2020-12	China
Evaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine NCT07263295 · ClinicalTrials.gov ↗ · Diaphragmatic Function, Metacarpal Fracture, Radius Fracture Drug: Liposomal bupivacaine	Not applicable	Recruiting	2025-12	China
CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases NCT06787560 · ClinicalTrials.gov ↗ · Bone Marrow Failure Syndrome	Phase EARLY_PHASE1	Recruiting	2025-01	China
A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China NCT05886114 · ClinicalTrials.gov ↗ · Cognitive Impairment, Alzheimer Disease, Vascular Cognitive Impairment	Not applicable	Recruiting	2023-05	China
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC) NCT06220617 · ClinicalTrials.gov ↗ · Colorectal Cancer, Adenomatous Polyps, Adenoma	Observational	Recruiting	2024-01	China
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) NCT06644118 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 1	Recruiting	2024-10	China
Placement of Biliary Drainage Stent to Prevent Biliary Intestinal Anastomosis After Liver Transplantation in Children NCT06048445 · ClinicalTrials.gov ↗ · Liver Transplant; Complications	Observational	Recruiting	2023-02	China
COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients NCT07012772 · ClinicalTrials.gov ↗ · Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis	Phase 2	Recruiting	2025-06	China
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia NCT07429461 · ClinicalTrials.gov ↗ · B-Cell Acute Lymphoblastic Leukemia	Phase EARLY_PHASE1	Recruiting	2026-02	China
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma NCT06676982 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 1	Recruiting	2025-01	China
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD NCT06769191 · ClinicalTrials.gov ↗ · Schimke Immuno-osseous Dysplasia	Phase EARLY_PHASE1	Recruiting	2025-01	China
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC NCT05837052 · ClinicalTrials.gov ↗ · Unresectable Lung Non-Small Cell Carcinoma	Phase 2	Recruiting	2023-05	China
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus NCT06920433 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase EARLY_PHASE1	Recruiting	2025-04	China
Feasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study NCT07051980 · ClinicalTrials.gov ↗ · Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis	Phase 2	Recruiting	2025-06	China
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia NCT07359586 · ClinicalTrials.gov ↗ · Gastric Cancer, Hepatic Carcinoma, Pulmonary Carcinoma	Observational	Recruiting	2025-11	China
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia NCT06762132 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase EARLY_PHASE1	Recruiting	2025-01	China
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma NCT06461624 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma	Phase 1	Recruiting	2024-07	China
The Jiaxing Birth Cohort in China NCT03217656 · ClinicalTrials.gov ↗ · Childhood Obesity, Anemia, Pregnancy Complications	Observational	Recruiting	1999-01	China
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases NCT04662294 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma	Phase EARLY_PHASE1	Recruiting	2021-11	China
HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation NCT07240766 · ClinicalTrials.gov ↗ · Borderline Resectable Pancreatic Adenocarcinoma Drugs: HRS-4642, Nimotuzumab	Phase 2	Recruiting	2026-02	China
A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) NCT07039201 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Not applicable	Recruiting	2025-06	China
Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy NCT07104214 · ClinicalTrials.gov ↗ · Gastric Cancer Stage, Esophageal Cancer, Gastroparesis	Observational	Recruiting	2025-08	China
IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia NCT07257640 · ClinicalTrials.gov ↗ · Hematologic Diseases, Neoplasms	Phase 1	Recruiting	2025-11	China
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma NCT05155189 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: C-CAR031, Durvalumab, Lenvatinib	Phase 1	Recruiting	2022-02	China
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia NCT06793241 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia	Phase EARLY_PHASE1	Recruiting	2025-01	China
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies NCT04603872 · ClinicalTrials.gov ↗ · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse	Phase EARLY_PHASE1	Recruiting	2020-11	China
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma NCT04657861 · ClinicalTrials.gov ↗ · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory	Phase EARLY_PHASE1	Recruiting	2022-05	China
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases NCT05827835 · ClinicalTrials.gov ↗ · Hematologic Diseases, Neoplasms	Phase 1/2	Recruiting	2023-04	China
Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma NCT07123545 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC)	Phase 1/2	Recruiting	2025-08	China
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer NCT05731726 · ClinicalTrials.gov ↗ · pMMR, MSS, MSI-L Drugs: Capecitabine, Celecoxib, Oxaliplatin	Phase 2	Recruiting	2023-02	China
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research NCT06711146 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus	Phase EARLY_PHASE1	Recruiting	2024-12	China
The Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy NCT07049094 · ClinicalTrials.gov ↗ · Brain Tumor Adult, Cerebrovascular Disease	Phase 4	Recruiting	2025-06	China
High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients NCT07307560 · ClinicalTrials.gov ↗ · Hypoxia, Esophageal Cancer, Gastric Cancer (Diagnosis)	Not applicable	Recruiting	2025-12	China
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients NCT07175155 · ClinicalTrials.gov ↗ · Hypoxemia, Esophageal Cancer, Morbidly Obese Patients	Not applicable	Recruiting	2025-10	China
KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia NCT07246707 · ClinicalTrials.gov ↗ · B-ALL Drug: KSV01	Phase 1	Recruiting	2026-01	China
TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients NCT07480785 · ClinicalTrials.gov ↗ · Uterine Fibroids (Leiomyoma), Ovarian Tumors, Gallstones	Not applicable	Recruiting	2026-01	China
CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma NCT04661020 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL)	Phase 2	Recruiting	2020-12	China
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma NCT06995105 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma (HCC) Drugs: Bevacizumab, Sintilimab	Phase 1/2	Recruiting	2025-04	China
Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients NCT07252102 · ClinicalTrials.gov ↗ · Liver Cirrhosis, Polyps of Colon, Gastrointestinal Dysfunction	Not applicable	Recruiting	2025-11	China
Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy NCT06082050 · ClinicalTrials.gov ↗ · Transthyroxin Amyloidosis Cardiomyopathy	Phase EARLY_PHASE1	Recruiting	2023-11	China
China Colorectal Cancer Screening Trial 1 (C-Cost1) NCT07090291 · ClinicalTrials.gov ↗ · Colorectal Cancer, Advanced Adenoma	Not applicable	Recruiting	2025-08	China
A Multicenter Study of CAR-T Cells in Primary Ph+All NCT07252336 · ClinicalTrials.gov ↗ · ALL	Phase 2	Recruiting	2025-11	China
CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia NCT06633328 · ClinicalTrials.gov ↗ · Aplastic Anemia	Phase EARLY_PHASE1	Recruiting	2024-10	China
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL NCT06633354 · ClinicalTrials.gov ↗ · T-Acute Lymphoblastic Leukemia	Phase EARLY_PHASE1	Recruiting	2024-10	China
The Use of Islet Organoids in the Treatment of Pancreatic Surgery-related Diabetes NCT06415643 · ClinicalTrials.gov ↗ · T3c Diabetes	Not applicable	Recruiting	2024-08	China
MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors NCT06912152 · ClinicalTrials.gov ↗ · B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors	Phase 1	Recruiting	2025-05	China
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer NCT06770439 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancers Drugs: Albumin-Bound Paclitaxel, Gemcitabine, IBI343	Phase 2	Recruiting	2025-04	China
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research NCT06716164 · ClinicalTrials.gov ↗ · Non-hodgkin Lymphoma,B Cell	Phase EARLY_PHASE1	Recruiting	2024-12	China
A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases NCT07789210 · ClinicalTrials.gov ↗ · Colorectal Cancer, BRAF V600E Mutation Positive, Encorafenib	Phase 2	Recruiting	2026-06	China
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL NCT06346912 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell	Phase EARLY_PHASE1	Recruiting	2024-05	China
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer NCT07257653 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, RAS, BRAF	Phase 2	Recruiting	2025-10	China
Physician and Patient Preferences for Cell Therapies in Advanced Solid Tumors NCT07813000 · ClinicalTrials.gov ↗ · Solid Tumors	Observational	Recruiting	2026-09	China
A Retrospective Study on the Relationship Between Donor Leukocyte Telomere Length and Prognosis of Acute Leukemia Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation NCT06076226 · ClinicalTrials.gov ↗ · Acute Leukemia	Observational	Recruiting	2015-01	China
A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies NCT04532203 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma	Phase EARLY_PHASE1	Recruiting	2020-11	China
Study of Comparing of With and Without Sequential Therapy of S-1 NCT05813015 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect Drugs: Docetaxel, Tegafur Gimeracil Oteracil	Phase 3	Recruiting	2023-01	China
A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery NCT07480044 · ClinicalTrials.gov ↗ · Postoperative Delirium (POD), Prostate Cancer, Kidney Tumor	Not applicable	Not yet open	2026-03	China
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis NCT06933563 · ClinicalTrials.gov ↗ · Myasthenia Gravis	Phase EARLY_PHASE1	Not yet open	2025-04	China
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. NCT06888674 · ClinicalTrials.gov ↗ · Pancreatic Cancer Resectable Drugs: Capecitabine, Gemcitabine, Sintilimab	Phase 1/2	Not yet open	2025-04	China
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer NCT07415525 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma Drug: IBI343	Phase 2	Not yet open	2026-02	China
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia NCT04658004 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase EARLY_PHASE1	Not yet open	2021-01	China
Early Diagnosis of Pancreatic Cancer Via Deciphering Multi-modal Immunological Signatures NCT06495749 · ClinicalTrials.gov ↗ · Pancreatic Cancer Resectable	Observational	Not yet open	2024-08	China
LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies NCT04657965 · ClinicalTrials.gov ↗ · Infectious Diseases, Hematological Malignancies	Phase EARLY_PHASE1	Not yet open	2021-01	China
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer NCT06759090 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Carcinoma Drugs: Apatinib Mesylate, Camrelizumab, Metronomic Capecitabine	Phase 2	Not yet open	2025-01	China
Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma NCT06848920 · ClinicalTrials.gov ↗ · Differentiated Thyroid Carcinoma (DTC), Neoadjuvant Therapy	Phase 2	Not yet open	2025-03	China
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer NCT07736612 · ClinicalTrials.gov ↗ · Pancreatic Cancer, RAS Mutations or Amplifications Drugs: Adebrelimab, HRS-2329, HS-20093	Phase 1/2	Not yet open	2026-08	China
Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study NCT06753513 · ClinicalTrials.gov ↗ · Malignant Tumors, Solid Tumor Malignancy	Observational	Not yet open	2024-12	China
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer. NCT06888648 · ClinicalTrials.gov ↗ · Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable Drug: Sintilimab	Phase 1/2	Not yet open	2025-04	China
Effectiveness of Artificial Intelligence-Assisted Colonoscopy for Adenoma Detection in Routine Clinical Practice : a Prospective Multicenter Randomized Trial NCT07307547 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Colonic Polyp, Adenoma	Not applicable	Not yet open	2026-09	China
Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy NCT07563075 · ClinicalTrials.gov ↗ · Hypoxemia, Pneumonia, Pulmonary Neoplasm	Not applicable	Not yet open	2026-04	China
High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease NCT07791979 · ClinicalTrials.gov ↗ · Hypoxemia, Gastric Cancer (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD)	Not applicable	Not yet open	2026-08	China
Research of the Application of Artificial Intelligence Model "PANDA" NCT06528223 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Not applicable	Not yet open	2024-08	China
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study NCT06922916 · ClinicalTrials.gov ↗ · COPD, Interstitial Pneumonia, Bronchiectasis	Observational	Not yet open	2025-04	China
Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study NCT07729917 · ClinicalTrials.gov ↗ · Bile Duct Carcinoma, Cholangiocarcinoma	Phase 2	Not yet open	2026-08	China
A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy NCT04541368 · ClinicalTrials.gov ↗ · Relapse Multiple Myeloma	Phase EARLY_PHASE1	Not yet open	2020-12	China
Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation NCT07637721 · ClinicalTrials.gov ↗ · Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis	Not applicable	Not yet open	2026-06	China
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma NCT07487402 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase EARLY_PHASE1	Not yet open	2026-03	China
CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD NCT05699746 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: Capecitabine, Oxaliplatin	Phase 3	Not yet open	2023-03	China
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia NCT04599543 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase EARLY_PHASE1	Not yet open	2020-11	China
Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological Malignancies NCT04662788 · ClinicalTrials.gov ↗ · Hematological Malignancies	Phase EARLY_PHASE1	Not yet open	2021-01	China
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma NCT04670055 · ClinicalTrials.gov ↗ · Relapse Multiple Myeloma, Refractory Multiple Myeloma	Phase EARLY_PHASE1	Not yet open	2021-01	China
Video Double-Lumen Tube for Secondary Pulmonary Resection NCT07467005 · ClinicalTrials.gov ↗ · Lung Cancer, Pulmonary Nodule	Not applicable	Not yet open	2026-03	China
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma NCT04609241 · ClinicalTrials.gov ↗ · Relapsed and/or Refractory Acute Lymphoblastic Leukemia, Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma	Phase EARLY_PHASE1	Not yet open	2020-11	China
Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation Surgery NCT07644104 · ClinicalTrials.gov ↗ · Thoracic Surgery With One-lung Ventilation, Lung Isolation, Bronchial Blockage	Not applicable	Not yet open	2026-08	China
A Study of CAR-T Cells in Subjects with Autoimmune Diseases NCT06762119 · ClinicalTrials.gov ↗ · Autoimmune Diseases	Phase EARLY_PHASE1	Not yet open	2025-01	China

Showing the 100 most recently updated of 110 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Zhejiang University trials

30 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Zhejiang University trials

159 conditions

Colorectal Cancer6 Esophageal Cancer5 Acute Myeloid Leukemia5 Pancreatic Cancer4 Gastric Cancer3Choledocholithiasis With Cholecystitis With Obstruction3Obstructive Jaundice3Pancreatitis3Cholelithiasis3Advanced Hepatocellular Carcinoma3 Hypoxemia3 Advanced Hepatocellular Carcinoma (HCC)3Metastatic Pancreatic Carcinoma2Pancreatic Cancer Resectable2 Hypoxia2Borderline Resectable Pancreatic Adenocarcinoma2Autoimmune Diseases2 Acute Lymphoblastic Leukemia2 Hematological Malignancies2Cetuximab N012Adenoma2Advanced Adenoma2Multiple Myeloma2 Systemic Lupus Erythematosus2

By trial register

Register	Trials	Recruiting
Clinical trials in China	110	71

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Colorectal Cancer

Sponsor	Trials
Fudan University	19
A2 Biotherapeutics	3
Nanchong Central Hospital	3
First Affiliated Hospital of Chongqing Medical University	3
Singlera Genomics	3
Verastem	2
Exelixis	2
IDEAYA Biosciences	2
Exact Sciences Corporation	2
HUYABIO International	2

Sponsors with the most current trials registered for this condition.

Questions about Zhejiang University trials

How many clinical trials does Zhejiang University sponsor?

Zhejiang University is the lead sponsor of 110 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Zhejiang University trials recruiting?

Yes. 71 of its 110 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Zhejiang University testing?

Its current trials name 30 drugs and biologicals as interventions. The most frequent are Gemcitabine (4), Sintilimab (4), Capecitabine (3), Nimotuzumab (3) and HRS-4642 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Zhejiang University clinical trials